Clinical Trial Details
| Trial ID: | L3432 |
| Source ID: | NCT00297063 |
| Associated Drug: | Rosiglitazone |
| Title: | BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy- |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: Rosiglitazone |
| Outcome Measures: | Primary: HbA1c change from baseline at Week 28., 28 Weeks | Secondary: Efficacy variables (changes from baseline in FPG, fasting insulin, HOMA-IR and HOMA-beta) at stipulated date in each treatment group., 28 Weeks |
| Sponsor/Collaborators: | Sponsor: GlaxoSmithKline |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE3 |
| Enrollment: | 350 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: |Primary Purpose: TREATMENT |
| Start Date: | 2006-01-11 |
| Completion Date: | 2007-05-31 |
| Results First Posted: | |
| Last Update Posted: | 2022-11-18 |
| Locations: | GSK Investigational Site, Fukuoka, 819-0168, Japan|GSK Investigational Site, Fukushima, 962-0856, Japan|GSK Investigational Site, Hokkaido, 051-0005, Japan|GSK Investigational Site, Ibaraki, 311-0113, Japan|GSK Investigational Site, Kanagawa, 224-0024, Japan|GSK Investigational Site, Kyoto, 615-0035, Japan|GSK Investigational Site, Nagano, 399-0006, Japan|GSK Investigational Site, Osaka, 577-0803, Japan|GSK Investigational Site, Saitama, 349-1105, Japan|GSK Investigational Site, Shizuoka, 424-0855, Japan|GSK Investigational Site, Tokyo, 125-0054, Japan|GSK Investigational Site, Tokyo, 130-0004, Japan|GSK Investigational Site, Tokyo, 160-0017, Japan|GSK Investigational Site |
| URL: | https://clinicaltrials.gov/show/NCT00297063 |
